Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2026-02-10 @ 10:31 AM
Study NCT ID:
NCT02720120
Status:
TERMINATED
Last Update Posted:
2016-03-28
First Post:
2016-03-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C533411', 'term': 'ocrelizumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 175}}, 'statusModule': {'whyStopped': 'The overall benefit risk profile of ocrelizumab was not favorable in RA', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2005-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-03', 'completionDateStruct': {'date': '2013-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-03-25', 'studyFirstSubmitDate': '2016-03-22', 'studyFirstSubmitQcDate': '2016-03-24', 'lastUpdatePostDateStruct': {'date': '2016-03-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2016-03-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs)', 'timeFrame': 'Baseline up to approximately 7.25 years'}, {'measure': 'Percentage of Participants with Anti-Ocrelizumab Antibodies', 'timeFrame': 'Baseline up to approximately 7.25 years'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants with American College of Rheumatology (ACR) 20%, 50%, and 70% (ACR20/50/70) Response at Week 24', 'timeFrame': 'Week 24'}, {'measure': 'Disease Activity Score at Week 24', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Participants achieving European League Against Rheumatism (EULAR) Response at Week 24', 'timeFrame': 'Week 24'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Time to Blood B-Cell Depletion', 'timeFrame': 'Baseline up to approximately 7.25 years'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration AUC(0-last) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Time to Maximum Observed Plasma Concentration (Tmax) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Terminal Rate Constant of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Systemic Clearance (CL) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Mean Residence Time (MRT) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Steady State Volume of Distribution (Vss) of Ocrelizumab', 'timeFrame': 'Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)'}, {'measure': 'Duration of Blood B-Cell Depletion', 'timeFrame': 'Baseline up to approximately 7.25 years'}]}, 'conditionsModule': {'conditions': ['Rheumatoid Arthritis']}, 'descriptionModule': {'briefSummary': 'This study is in two parts and will evaluate the safety, tolerability and efficacy of escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation study, at one of the following dose levels of ocrelizumab \\[400, 1000, 1500, and 2000 milligrams (mg)\\]. In Part 2, participants will be randomized to explore tolerability and efficacy of doses which have been shown to be tolerated in Part 1.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Moderate to severe RA for at least 6 months\n* Positive serum rheumatoid factor (\\>/= 20 international units per milliliter)\n* Current treatment with RA on an outpatient basis\n* Treatment failure with one disease modifying anti-rheumatic drug (DMARD) or biologic, but have not failed more than six of these agents including methotrexate\n* Current treatment with methotrexate for at least 12 weeks, at a stable dose\n* Use of highly effective contraception.\n\nExclusion Criteria:\n\n* Rheumatic autoimmune disease or inflammatory joint disease, other than RA\n* Concurrent treatment with any disease-modifying anti-rheumatic drug (DMARD) (other than methotrexate) or any anti-tumor necrosis factor (TNF) -alfa or other biologic therapy\n* Treatment with any other investigational drug within 4 weeks of screening\n* Previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular or parenteral corticosteroids, and receipt of live/attenuated vaccine prior to screening\n* Previous treatment with rituximab or any other anti-cluster of differentiation 20 (CD20) agent\n* History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies\n* Known active bacterial, viral or fungal infections\n* History of active tuberculosis and primary or secondary immunodeficiency\n* History of concomitant diseases such as cardiovascular disease, nervous system, pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders\n* Pregnancy or lactation.'}, 'identificationModule': {'nctId': 'NCT02720120', 'briefTitle': 'A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response', 'orgStudyIdInfo': {'id': 'WA18230'}, 'secondaryIdInfos': [{'id': '2004-002132-26', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1: Ocrelizumab 1000 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 1000 mg.', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1: Ocrelizumab 1500 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 1500 mg.', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1: Ocrelizumab 2000 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 2000 mg.', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1: Ocrelizumab 400 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part 1: Placebo', 'description': 'Participants will receive single IV infusion of placebo matched to ocrelizumab.', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Ocrelizumab 1000 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 1000 mg.', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Ocrelizumab 1500 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 1500 mg.', 'interventionNames': ['Drug: Ocrelizumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2: Ocrelizumab 400 mg', 'description': 'Participants will receive single IV infusion of ocrelizumab 400 mg.', 'interventionNames': ['Drug: Ocrelizumab']}], 'interventions': [{'name': 'Ocrelizumab', 'type': 'DRUG', 'otherNames': ['RO4964913, rhuMAb 2H7, PRO70769'], 'description': 'Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.', 'armGroupLabels': ['Part 1: Ocrelizumab 1000 mg', 'Part 1: Ocrelizumab 1500 mg', 'Part 1: Ocrelizumab 2000 mg', 'Part 1: Ocrelizumab 400 mg', 'Part 2: Ocrelizumab 1000 mg', 'Part 2: Ocrelizumab 1500 mg', 'Part 2: Ocrelizumab 400 mg']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive single IV infusion of placebo.', 'armGroupLabels': ['Part 1: Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '2010', 'city': 'Darlinghurst', 'state': 'New South Wales', 'country': 'Australia', 'geoPoint': {'lat': -33.87939, 'lon': 151.21925}}, {'zip': '5041', 'city': 'Adelaide', 'state': 'South Australia', 'country': 'Australia', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '3004', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '6979', 'city': 'Perth', 'state': 'Western Australia', 'country': 'Australia', 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'zip': '9000', 'city': 'Ghent', 'country': 'Belgium', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': 'T2N 4Z6', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'T6G 2S2', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'N6A 4V2', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'M4N 3M5', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'M5G 1X5', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'M5T 2S8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'G1V 3M7', 'city': 'Québec', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': 'J1H 5N4', 'city': 'Sherbrooke', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.40008, 'lon': -71.89908}}, {'zip': '1105 AZ', 'city': 'Amsterdam', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '0620', 'city': 'Auckland', 'country': 'New Zealand', 'geoPoint': {'lat': -36.84853, 'lon': 174.76349}}, {'zip': '2025', 'city': 'Auckland', 'country': 'New Zealand', 'geoPoint': {'lat': -36.84853, 'lon': 174.76349}}, {'zip': '115522', 'city': 'Moscow', 'country': 'Russia', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '119049', 'city': 'Moscow', 'country': 'Russia', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '129110', 'city': 'Moscow', 'country': 'Russia', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '129327', 'city': 'Moscow', 'country': 'Russia', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '190068', 'city': 'Saint Petersburg', 'country': 'Russia', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '194291', 'city': 'Saint Petersburg', 'country': 'Russia', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '195067', 'city': 'Saint Petersburg', 'country': 'Russia', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '08025', 'city': 'Barcelona', 'state': 'Barcelona', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08035', 'city': 'Barcelona', 'state': 'Barcelona', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '11009', 'city': 'Cadiz', 'state': 'Cadiz', 'country': 'Spain', 'geoPoint': {'lat': 36.52672, 'lon': -6.2891}}, {'zip': '18003', 'city': 'Granada', 'state': 'Granada', 'country': 'Spain', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'state': 'La Coruña', 'country': 'Spain', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '28922', 'city': 'Alcorcón', 'state': 'Madrid', 'country': 'Spain', 'geoPoint': {'lat': 40.34582, 'lon': -3.82487}}, {'zip': '28041', 'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28222', 'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28935', 'city': 'Madrid', 'state': 'Madrid', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41014', 'city': 'Seville', 'state': 'Sevilla', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '38320', 'city': 'San Cristóbal de La Laguna', 'state': 'Tenerife', 'country': 'Spain', 'geoPoint': {'lat': 28.4853, 'lon': -16.32014}}, {'zip': '46017', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': 'AB25 2ZD', 'city': 'Aberdeen', 'country': 'United Kingdom', 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'zip': 'CB2 2QQ', 'city': 'Cambridge', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'DE22 3NE', 'city': 'Derby', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.92277, 'lon': -1.47663}}, {'zip': 'LS1 3EX', 'city': 'Leeds', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'L9 7AL', 'city': 'Liverpool', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'E11 1NR', 'city': 'London', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE1 9RT', 'city': 'London', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'ME16 9QQ', 'city': 'Maidstone', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.26667, 'lon': 0.51667}}, {'zip': 'NE1 4LP', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'NR4 7UY', 'city': 'Norwich', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}, {'zip': 'M6 8HD', 'city': 'Salford', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.48771, 'lon': -2.29042}}, {'zip': 'TQ2 7AA', 'city': 'Torquay', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.46198, 'lon': -3.52522}}, {'zip': 'M41 5SL', 'city': 'West Midlands', 'country': 'United Kingdom'}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}